Tenofovir induced Fanconi syndrome: A possible pharmacokinetic interaction

Indian Journal of Pharmacology

Volumn 45, Issue 2, 2013, Pages 191-192

  Kapadia, Jigar ^a   Shah, Samidh ^a   Desai, Chetna ^a   Desai, Mira ^a   Patel, Shivani ^a   Shah, Asha ^b   Dikshit, R ^a  

^a B J MEDICAL COLLEGE   (India)

^b CIVIL HOSPITAL   (India)

Author keywords

Adverse drug reaction; Fanconi syndrome; protease inhibitor; tenofovir

Indexed keywords

ABACAVIR; COTRIMOXAZOLE; DIDANOSINE; FOLIC ACID; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LOPINAVIR; MULTIVITAMIN; PHOSPHATE; TENOFOVIR;

ADULT; ALBUMINURIA; ANKLE EDEMA; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CD4 LYMPHOCYTE COUNT; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FOLLOW UP; GLUCOSURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KNEE PAIN; MALE; PHOSPHATE BLOOD LEVEL; PRESCRIPTION; URINALYSIS; URINARY FREQUENCY; VIRUS LOAD;

ADVERSE DRUG REACTION; FANCONI SYNDROME; PROTEASE INHIBITOR; TENOFOVIR;

ADENINE; ALBUMINURIA; ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FANCONI SYNDROME; GLYCOSURIA; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPOPHOSPHATEMIA; INDIA; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; RITONAVIR; TIME FACTORS;

EID: 84875980587     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.108319     Document Type: Article

References (11)

1. Flexner C. Antiretroviral agents and treatment of HIV infection. The pharmacological Basis of Therapeutics. 11th ed. New York: McGraw Hill; 2006. p. 1290-1
2. Mathew G, Knaus SJ. Acquired Fanconi's syndrome associated with tenofovir therapy. J Gen Intern Med 2006;21:C3-5
3. Rollot F, Nazal EM, Chauvelot-Moachon L, Kélaïdi C, Daniel N, Saba M, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: The role of lopinavirritonavir-didanosine. Clin Infect Dis 2003;37:e174-6
4. Asplin JR, Coe FL. Tubular disorders. In: Kasper D, Braunwald E, Fauci A, Hauser S, Longo D, Jameson J, editors. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw Hill; 2005. p. 1701
5. Who-umc.org. The Uppsala Monitoring Centre. Available from: Http://www. who-umc.org/DynPage.aspx?id=22682. [Last accessed 2010 sep 24]. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics, 1981;30:239-245
6. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992;49:2229-32
7. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992;27:538
8. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-Associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis 2006;42:283-90
9. Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-Associated renal dysfunction in clinical practice: An observational cohort from western India. Indian J Sex Transm Dis 2010;31:30-4
10. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C et al. Greater tenofovirassociated renal function decline with protease inhibitor-based versus nonnucleoside reverse-Transcriptase inhibitor-based therapy. Journal of Infectious Diseases. 2008;197:102-108
11. Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 2005;49:3361-6